Characterization of mesentericin ST99, a bacteriocin produced by Leuconostoc mesenteroides subsp. dextranicum ST99 isolated from boza.
Lactic acid bacteria isolated from Boza, a cereal-fermented beverage from Belogratchik, Bulgaria, were screened for the production of bacteriocins. With the first screening, 13 of the 52 isolates inhibited the growth of Listeria innocua and Lactobacillus plantarum. The cell-free supernatant of one of these strains, classified as Leuconostoc mesenteroides subsp. dextranicum ST99, inhibited the growth of Bacillus subtilis, Enterococcus faecalis, several Lactobacillus spp., Lactococcus lactis subsp. cremoris, Listeria innocua, Listeria monocytogenes, Pediococcus pentosaceus, Staphylococcus aureus and Streptococcus thermophilus. Clostridium spp., Carnobacterium spp., L. mesenteroides and Gram-negative bacteria were not inhibited. Maximum antimicrobial activity, i.e. 6,400 arbitrary units (AU)/ml, was recorded in MRS broth after 24 h at 30 degrees C. Incubation in the presence of protease IV and pronase E resulted in loss of antimicrobial activity, confirming that growth inhibition was caused by a bacteriocin, designated here as mesentericin ST99. No loss in activity was recorded after treatment with alpha-amylase, SDS, Tween 20, Tween 80, urea, Triton X-100, N-laurylsarcosin, EDTA and phenylmethylsulfonylfluoride. Mesentericin ST99 remained active after 30 min at 121 degrees C and after 2 h of incubation at pH 2 to 12. Metabolically active cells of L. innocua treated with mesentericin ST99 did not undergo lysis. Mesentericin ST99 did not adhere to the cell surface of strain ST99. Precipitation with ammonium sulfate (70% saturation), followed by Sep-Pack C18 chromatography and reverse-phase HPLC on a C18 Nucleosil column yielded one antimicrobial peptide.
Todorov
Svetoslav D
SD
Department of Microbiology, University of Stellenbosch, 7600, Stellenbosch, South Africa.
Dicks
Leon M T
LM
D000900:Anti-Bacterial Agents / Q000096:biosynthesis / Q000378:metabolism / Q000494:pharmacology; D001412:Bacillus subtilis / Q000187:drug effects / Q000254:growth & development; D001430:Bacteriocins / Q000096:biosynthesis* / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology*; D002614:Chelating Agents / Q000494:pharmacology; D003013:Clostridium / Q000187:drug effects / Q000254:growth & development; D003470:Culture Media / Q000737:chemistry; D006090:Gram-Negative Bacteria / Q000187:drug effects / Q000254:growth & development; D006863:Hydrogen-Ion Concentration; D007778:Lactobacillus / Q000187:drug effects / Q000254:growth & development; D007934:Leuconostoc / Q000378:metabolism*; D008087:Listeria / Q000187:drug effects / Q000254:growth & development; D010447:Peptide Hydrolases / Q000378:metabolism; D011402:Pronase / Q000378:metabolism; D011480:Protease Inhibitors / Q000494:pharmacology; D013211:Staphylococcus aureus / Q000187:drug effects / Q000254:growth & development; D013289:Streptococcaceae / Q000187:drug effects / Q000254:growth & development; D013501:Surface-Active Agents / Q000494:pharmacology; D013696:Temperature; D000516:alpha-Amylases / Q000378:metabolism
D000900:Anti-Bacterial Agents; D001430:Bacteriocins; D002614:Chelating Agents; D003470:Culture Media; D011480:Protease Inhibitors; D013501:Surface-Active Agents; D000516:alpha-Amylases; D010447:Peptide Hydrolases; D011402:Pronase; C030732:protease IV